Jun 2026 (Q2 FY26) — Aug 12, 2026
Humacyte Q2 FY26 — Breakthrough Dialysis Trial Results and Commercial Rebuild
Read the full callHumacyte (HUMA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Humacyte earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.41 | +34.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -6649.3 | +3226.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -36.8 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.4 −6.98% · −$0.03
Performance −76.7% 1Y
1Y: $1.72 on 17 Oct 2025 → $0.4. High $1.81 (20 Oct 2025), low $0.35 (14 Oct 2026).
- Previous close
- $0.43
- 52-week range
- $0.35 – $1.81
- One year
- −77.90%
Overview
- Symbol
- HUMA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Humacyte earnings calls (HUMA)
Financials
What the filings say
Net profit, year on year: +2% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Expenses | 30 | 28 | 24 | 30 | 25 | 31 | 29 | 27 |
| Operating profit | -30 | -28 | -23 | -30 | -24 | -31 | -29 | -27 |
| Operating margin | — | — | −4484.3% | −9876.1% | −3239.0% | −6603.0% | −5845.4% | −6649.3% |
| Other income | -9 | 7 | 62 | -8 | 7 | 6 | 11 | -10 |
| Interest | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Net profit | -39 | -21 | 39 | -38 | -18 | -25 | -18 | -37 |
| EPS ($ per share) | -0.33 | — | 0.28 | -0.24 | -0.11 | — | -0.09 | -0.16 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -388 | -415 | -427 | -537 | -686 | -727 |
| Total liabilities | 36 | 164 | 87 | 115 | 191 | 113 |
| Fixed assets | 41 | 35 | 30 | 27 | 23 | 19 |
| Investments | 0 | 8 | 2 | 0 | — | — |
| Total assets | 107 | 287 | 204 | 128 | 138 | 116 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -56 | -81 | -71 | -73 | -98 | -105 |
| Cash from investing | -0 | -8 | 5 | -0 | -2 | -1 |
| Cash from financing | 2 | 267 | -1 | 5 | 114 | 61 |
| Net cash flow | -54 | 178 | -68 | -69 | 14 | -44 |
| Capital expenditure | -0 | -0 | -1 | -2 | -2 | -1 |
| Free cash flow | -56 | -81 | -72 | -76 | -100 | -106 |
Insider filings
9 filings between Nov 16, 2025 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
$90.2K
5 purchases by 3 insiders
Sales
$82.3K
2 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 2
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Sebelius Kathleen | $50.0K | — | May 19, 2026 |
| Sander Dale A. | — | $41.1K | May 18, 2026 |
| Parikh Shamik J | — | $41.1K | May 18, 2026 |
| Jones Keith Anthony | $30.4K | — | Sep 14, 2026 |
| Constantino Michael T. | $9.8K | — | May 18, 2026 |
Latest filings (41)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Jones Keith Anthony Director | Purchase | 10,000 | $5.6K |
| Aug 20, 2026 | Jones Keith Anthony Director | Purchase | 10,000 | $6.9K |
| Aug 17, 2026 | Jones Keith Anthony Director | Purchase | 30,000 | $17.8K |
| May 19, 2026 | Sebelius Kathleen Director | Purchase | 56,818 | $50.0K |
| May 18, 2026 | Sander Dale A. CFO and Chief Corp. Dev. Off | Sale 10b5-1 plan | 45,887 | $41.1K |
| May 18, 2026 | Parikh Shamik J Chief Medical Officer | Sale 10b5-1 plan | 45,887 | $41.1K |
| May 18, 2026 | Constantino Michael T. Director | Purchase | 11,000 | $9.8K |
| Nov 16, 2025 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Award | 311,100 | $0 |
| Nov 16, 2025 | Parikh Shamik J Chief Medical Officer | Award | 311,100 | $0 |
| Aug 20, 2025 | Dougan Brady W Director | Sale | 591,685 | $934.9K |
| Aug 20, 2025 | Niklason Laura E President, CEO and Director | Sale | 591,685 | $934.9K |
| Aug 19, 2025 | Niklason Laura E President, CEO and Director | Sale | 1,100,000 | $1.79M |
| Aug 19, 2025 | Dougan Brady W Director | Sale | 1,100,000 | $1.79M |
| Aug 18, 2025 | Niklason Laura E President, CEO and Director | Sale | 549,360 | $1.01M |
| Aug 18, 2025 | Dougan Brady W Director | Sale | 549,360 | $1.01M |
| Apr 14, 2025 | Scheessele William John Chief Commercial Officer | Purchase | 6,493 | $10.0K |
| Apr 10, 2025 | Parikh Shamik J Chief Medical Officer | Purchase | 7,500 | $11.6K |
| Apr 10, 2025 | Sander Dale A. CFO and Chief Corp. Deve. Off. | Purchase | 20,000 | $30.6K |
| Apr 8, 2025 | Green Charles Bruce Director | Purchase | 6,000 | $7.7K |
| Apr 8, 2025 | Sebelius Kathleen Director | Purchase | 50,000 | $66.0K |
| Apr 7, 2025 | Constantino Michael T. Director | Purchase | 16,000 | $20.2K |
| Dec 4, 2024 | Constantino Michael T. Director | Purchase | 4,600 | $20.2K |
| Nov 20, 2024 | Dougan Brady W Director | Sale | 261,369 | $1.15M |
| Nov 20, 2024 | Niklason Laura E President, CEO and Director | Sale | 261,369 | $1.15M |
| Nov 19, 2024 | Niklason Laura E President, CEO and Director | Purchase | 1,797 | $8.0K |
| Nov 19, 2024 | Dougan Brady W Director | Purchase | 1,797 | $8.0K |
| Nov 19, 2024 | Niklason Laura E President, CEO and Director | Sale | 427,459 | $1.86M |
| Nov 19, 2024 | Dougan Brady W Director | Sale | 427,459 | $1.86M |
| Nov 18, 2024 | Niklason Laura E President, CEO and Director | Sale | 811,172 | $3.60M |
| Nov 18, 2024 | Dougan Brady W Director | Sale | 811,172 | $3.60M |
| Sep 13, 2024 | Green Charles Bruce Director | Option exercise | 1,200 | $4.9K |
| Sep 10, 2024 | Niklason Laura E President, CEO and Director | Sale | 288,674 | $1.51M |
| Sep 10, 2024 | Dougan Brady W Director | Sale | 288,674 | $1.51M |
| Sep 10, 2024 | Sebelius Kathleen Director | Option exercise | 4,521 | $19.6K |
| Sep 10, 2024 | Sebelius Kathleen Director | Sale | 3,634 | $19.7K |
| Sep 10, 2024 | Sebelius Kathleen Director | Option exercise | 2,479 | $8.3K |
| Sep 10, 2024 | Sebelius Kathleen Director | Sale | 1,548 | $8.3K |
| Sep 9, 2024 | Dougan Brady W Director | Sale | 157,704 | $854.8K |
| Sep 9, 2024 | Niklason Laura E President, CEO and Director | Sale | 157,704 | $854.8K |
| Aug 29, 2024 | Dougan Brady W Director | Purchase | 1,222 | $8.0K |
| Aug 29, 2024 | Niklason Laura E President, CEO and Director | Purchase | 1,222 | $8.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Humacyte, Inc.
Free account. Everything above stays public.
Write why you follow Humacyte, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading